Watch for a New Buprenorphine Product for Opioid Use Disorder

October 2023

Brixadi will be another long-acting buprenorphine injectable used for moderate to severe opioid use disorder.

Expect these products to still be saved for when there are concerns about adherence, diversion, or misuse. They’re much more costly than generics, such as sublingual buprenorphine/naloxone tabs.

Help keep patients safe if you do get an Rx for Brixadi.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote